K. Yeleswaram et al., IN-VIVO DISPOSITION AND IN-VITRO METABOLISM OF AN ANXIOLYTIC COMPOUND, BMS-184111, IN RATS, Research communications in molecular pathology and pharmacology, 89(1), 1995, pp. 27-44
Plasma concentrations of BMS-184111, an anxiolytic, were determined as
a function of time following single intravenous, intraperitoneal and
oral administrations. In order to assess the brain penetration of this
compound, concentrations in whole brain samples were also determined
in the intravenous leg of the study. Concentrations of BMS-184111 in p
lasma and brain homogenate samples were determined using an HPLC assay
following liquid/liquid extraction. After intravenous administration,
BMS-184111 was eliminated from plasma with a half-life of about 3.6 h
ours. The brain/plasma AUC ratio for BMS-184111 concentration was 5.5,
indicating effective penetration of the compound into the brain. Comp
arison of the plasma AUC values obtained following intravenous and int
raperitoneal doses indicated that BMS-184111 was only 33% bioavailable
after intraperitoneal administration, suggesting that the compound un
dergoes significant first-pass hepatic extraction. The oral bioavailab
ility of BMS-184111 was found to be 10% after administration of the fr
ee base and 23% after administration of the hydrochloride salt. These
results suggest that BMS-184111 undergoes incomplete GI absorption and
/or intestinal metabolism in addition to first-pass hepatic extraction
. The in vitro metabolism of BMS-184111 was studied using rat liver ho
mogenate preparation (the 9000 g supernatant; S-9). Several of the met
abolites thus generated were profiled using LC/MS and LC/MS/MS. Metabo
lism of BMS-184111 in rat liver S-9 occurs through hydroxylation, O-de
methylation, and demethylenation.